Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : NOVARTIS FARMA
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension
To evaluate the long-term safety and tolerability of QTI571 in patients with severe pulmonary arterial hypertension.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
Study assessing the safety and tolerability of 0.5 mg ranibizumab in mono/bilateral wet AMD patients in eyes with BCVA below 2/10 and/or second affected eye. Studio per valutare la sicurezza e la tollerabilità di ranibizumab 0.5 mg in pazienti affetti da wAMD mono/bilaterale in occhi con BCVA inferiore a 2/10 e/o patologia del secondo occhio
The primary objective of the present study is to evaluate the annual incidence of both ocular and systemic drug-related adverse events following ranibizumab treatment in patients diagnosed with wAMD a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two doses of indacaterol (150 and 300 μg o.d.) in patients with chronic obstructive pulmonary disease
To assess the safety of two indacaterol doses (150 and 300 μg o.d. via SDDPI) in patients with moderate to severe COPD as compared to placebo after 52 weeks of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 and IV bortezomib in adult patients with multiple myeloma
To determine the MTD of LBH589 and bortezomib when administered in combination
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after failure of sorafenib treatment The EVOLVE-1 Study
The primary objective of this study is to compare overall survival between the combination treatment of everolimus plus BSC to placebo plus BSC in patients with advanced HCC whose disease progressed ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A 24-week randomized placebo-controlled, double-blind multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of severe pulmonary arterial hypertension: Imatinib in Pulmonary arterial hypertension, a Randomized, Efficacy Study (IMPRES)
To evaluate the efficacy of QTI571 compared to placebo as measured by the change in 6- minute walk distance (6MWD) from baseline to 24-weeks
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
Multicenter, randomized, open-label trial to evaluate the safety, tolerability and efficacy of two regimens of Everolimus plus Neoral, given according different blood target levels, in de novo renal transplant recipients Everest the upper target EVErolimus RandomizEd STudy
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A randomized, multi-center, parallel-group, open-label study to evaluate the therapeutical benefit of an initially intensified dosing regimen of Myfortic vs. a standard dosing regimen of Myfortic in combination with Neoral and Corticosteroids in de novo renal transplant patients Studio multicentrico, randomizzato, in aperto, a gruppi paralleli, per valutare l'efficacia di Myfortic a dose inizialmente intensificata in confronto a Myfortic a dose normale, in pazienti con trapianto di rene de novo in terapia con Neoral e corticosteroidi
To evaluate therapeutic benefit by comparing the efficacy defined as the proportion of patients with treatment failure (biopsy proven acute rejection, graft loss or death) at 6 month post transplant ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventricular hypertrophy in overwiight patients with essential hypertension
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Na ve Patients with Type 2 Diabetes
To demonstrate the efficacy of vildagliptin in elderly drug na ve patients with type 2 diabetes by testing the hypothesis that the hemoglobin A1c HbA1c reduction with vildagliptin 100 mg qd is not ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
3
4
5
6
7
8
9
Suivant